Europe Pharmaceutical Market to Reach USD 690.7 Billion by 2030, Growing at 5.9% CAGR - DataM Intelligence

According to the latest report published by DataM Intelligence, the Europe Pharmaceutical Market, valued at USD 488.05 billion in 2024, is expected to reach USD 690.7 billion by 2030, growing at a CAGR of 5.9% during the forecast period (2025-2030). The growth is primarily driven by an aging population, increasing healthcare expenditure, adoption of digital health technologies, and strong regulatory and R&D support fostering the development of advanced drug therapies.

Europe's pharmaceutical industry plays a pivotal role in global healthcare innovation, with countries such as Germany, France, the UK, and Italy leading in drug discovery and clinical trial activity. The region's focus on biologics, biosimilars, and personalized medicine is enhancing treatment precision and affordability across therapeutic areas such as oncology, cardiology, and immunology. Additionally, the European Medicines Agency (EMA) continues to streamline approval regulations and strengthen innovation frameworks to improve patient access to cutting-edge therapies.

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/biopharmaceuticals-market?utm_source=OpenPR&utm_campaign=Onkar

Key Highlights from the Report

➤ The Europe Pharmaceutical Market is forecasted to grow at a 5.9% CAGR, reaching USD 690.7 billion by 2030.
➤ Biologics & biosimilars emerge as the fastest-growing segment driven by demand for targeted and affordable therapies.
➤ Conventional small-molecule drugs continue to hold the majority share with 54.74% market presence.
➤ Branded pharmaceuticals represent 66.49% of total revenue, driven by innovation and novel drug launches.
➤ Germany, France, and the UK collectively account for the highest pharmaceutical R&D expenditure in Europe.
➤ Investments in digital health platforms and e-pharmacies support patient-centric access to medications.

Market Segmentation

By Molecule Type:

Conventional (small molecule) drugs dominated the European market with a share of 54.74% in 2024. These chemically synthesized therapies target a wide range of chronic conditions such as cardiovascular disease and hypertension. Despite the growing presence of biologics, small molecules remain central to European healthcare delivery due to their affordability, oral administration, and scalability.

Biologics and Biosimilars represent the fastest-growing market segment. Advances in gene therapy, monoclonal antibodies, and cell therapy are shaping innovative treatment pathways for oncology and autoimmune disorders. The EMA's accelerated approval for new biosimilars, such as Amgen's PAVBLU and CuraTeQ's DYRUPEG in 2025, reinforces the region's leadership in accessibility and affordability.

By Product Type:

Branded drugs dominated the market with a 66.49% revenue share, reflecting a strong innovation pipeline. In parallel, the generic drug segment is expanding rapidly driven by the expiration of multiple patents and heightened demand for cost-effective therapeutics. The regulatory environment ensures generics meet stringent safety and efficacy standards, positioning them as sustainable options for public healthcare systems.

By Disease Type:

Cancer accounted for 18.06% of market revenue in 2024, supported by rising prevalence and increased development of immuno-oncology drugs. Meanwhile, anti-obesity drugs are witnessing exponential demand, propelled by innovations such as GLP-1 receptor agonists and Biocon's 2025 launch of liraglutide in the UK. This diversification reflects Europe's growing focus on chronic metabolic and lifestyle-driven conditions.

By Route of Administration:

The oral route held the largest share (57.53% in 2024) due to its cost-effectiveness, convenience, and versatility in chronic disease management. The parenteral route is projected to grow rapidly, driven by the adoption of injectables, biologics, and self-administered delivery systems, including wearable injectors and prefilled syringes.

Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/biopharmaceuticals-market?utm_source=OpenPR&utm_campaign=Onkar

Regional Insights

Western Europe:

Countries such as Germany, France, and the UK continue to dominate the European market through significant public investment in healthcare infrastructure and drug manufacturing. Germany leads in exports, valued at over USD 338 billion in 2024. France's emphasis on reshoring essential drug production underpins strategic supply chain resilience, while the UK's thriving biotech ecosystem fosters innovation in mRNA and AI-driven therapies.

Southern and Eastern Europe:

Italy and Spain are emerging as key contributors to the regional market, focusing on oncology, biotechnology, and digital clinical research infrastructure. The introduction of cost-saving generic drugs and new R&D collaborations is helping these nations strengthen their presence. Eastern Europe's healthcare modernization initiatives, supported by the European Union, are expanding pharmaceutical access and production capacity.

Nordic Region:

Countries such as Denmark and Sweden are establishing robust frameworks for clinical trials and healthcare digitization. Denmark's R&D investment in biopharmaceuticals and Sweden's focus on sustainable drug pricing models demonstrate the region's commitment to balancing innovation with affordability.

Market Dynamics

Market Drivers:

The European pharmaceutical market is benefiting from an aging population, increasing healthcare spending, and technological advancements in biologics, immunotherapies, and digital medicine. Government-supported R&D incentives and an expanding pipeline for personalized treatments continue to strengthen competitiveness.

Market Restraints:

Stringent EMA approval requirements and high development costs limit smaller firms' entry into the market. Price pressures stemming from generic competition and supply chain dependence on external regions pose additional challenges.

Market Opportunities:

Digital health expansion, AI-based drug discovery, and e-pharmacy adoption are unlocking growth potential. The increasing focus on orphan drugs and rare disease therapies offers niche opportunities for specialized biotech firms across Europe.

Purchase This Exclusive Report at Just USD 4515 Only: https://www.datamintelligence.com/buy-now-page?report=biopharmaceuticals-market?utm_source=OpenPR&utm_campaign=Onkar

Reasons to Buy the Report

✔ In-depth analysis of Europe's market growth, segmentation, and competitive landscape.
✔ Insights into evolving regulatory trends and their impact on pharmaceutical innovation.
✔ Breakdown of biologics, biosimilars, and digital health integration shaping the sector's future.
✔ Evaluation of R&D initiatives and clinical trial developments by top pharmaceutical firms.
✔ Data-driven projections supporting strategic decisions in a dynamic healthcare environment.

Frequently Asked Questions (FAQs)

◆ How large is the Europe Pharmaceutical Market in 2024?
◆ What is the projected CAGR of the Europe Pharmaceutical Market through 2030?
◆ Which region within Europe holds the largest pharmaceutical manufacturing base?
◆ What are the growth opportunities in biologics and biosimilars for European developers?
◆ Who are the key players leading the Europe Pharmaceutical Market innovation?

Company Insights

F. Hoffmann-La Roche Ltd.

Bristol-Myers Squibb Company

AstraZeneca plc

Novartis AG

Johnson & Johnson Services, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Pfizer Inc.

Sanofi

Boehringer Ingelheim GmbH

Recent Developments:

In February 2025, Fennec Pharmaceuticals and Norgine Pharmaceuticals Ltd. announced the launch of PEDMARQSI (sodium thiosulfate injection) in Germany, expanding oncology supportive care options.

In January 2025, Lupin Limited and Avas Pharmaceuticals SRL introduced NaMuscla (mexiletine) in Italy for non-dystrophic myotonic disorder treatment.

In February 2025, Tiefenbacher Pharmaceuticals prepared to launch Varenicline, a smoking cessation therapy, in the UK to enhance preventive healthcare solutions.

Conclusion

The Europe Pharmaceutical Market is entering a transformative decade powered by biotechnology advancement, digital health adoption, and robust regulatory alignment across regions. With growing investments in R&D, innovations in biologics, and integration of AI-driven drug discovery, Europe remains at the forefront of healthcare innovation. Rising chronic disease prevalence, evolving clinical trial infrastructures, and government emphasis on sustainable healthcare access ensure long-term growth and competitiveness for the continent's pharmaceutical sector through 2030.

Contact Us

Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com

About Us

DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.

This release was published on openPR.